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Abstract 
Purpose: The Patient Health Questionnaire – 15 (PHQ-15) and the Somatic Symptom Scale – 
8 (SSS-8) are self-report measures which assess somatic symptom burden. The present study 
investigates whether the two measures are comparable in terms of their psychometric 
properties and estimates of symptom burden. 
Method: Item characteristics, reliability, symptom severity and construct validity with regard 
to other relevant psychological, health-related quality of life and disability measures were 
compared for the PHQ-15m and the SSS-8 in 294 primary care patients who participated in a 
randomized comparative effectiveness trial targeting pain and mood symptoms. 
Results: The reliabilities of the PHQ-15m and the SSS-8 were α = 0.66 and α = 0.72, 
respectively. Both measures were highly correlated (r = 0.79). All item characteristics were 
comparable and both instruments showed the same pattern of correlations with instruments 
measuring depression, anxiety, pain, quality of life and impairment (r = 0.25 to 0.53). A 1-
point score increase (worsening of somatic symptoms) on either instrument resulted in a 3.7% 
to 3.9% increase in the number of disability days reported for the last four weeks. Using the 
same severity thresholds (5: low, 10: medium, 15: high), both measures identified nearly 
identical subgroups of patients with regard to health-related quality of life and disability.  
Conclusion: The PHQ-15m and the SSS-8 are comparable measures in terms of reliability and 
validity and severity classifications. These findings are in line with previous results and 
support the use of the SSS-8 as a valuable and short alternative to the original PHQ-15 in 
settings with limited assessment time. 
Keywords: PHQ-15, SSS-8, somatic symptom burden, psychometrics 
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Introduction  
Somatic symptoms are ubiquitous in the general population; an estimated 80% of 
individuals will experience one or more somatic symptoms in any given month [1]. 
Symptoms may include pain as well as digestive, cardiovascular, pulmonary, urological, 
neurological, or sensory complaints. Many symptoms are neither exclusive correlates of an 
organic disease (e.g. cancer or coronary heart disease) nor exclusive symptoms of a 
psychiatric condition (e.g. depression or anxiety disorders) [2-4]. Somatic symptoms which 
are either part of a functional somatic syndrome, or otherwise unexplained by pathology, are 
the reason for at least 33% of primary care consultations and between 15 and 54% of 
specialist referrals across many medical disciplines. Usually, only those individuals who are 
actually distressed or impaired by their somatic symptoms present to clinical practice. About 
one fourth of all patients develops persistent symptoms [5].  
Persistent somatic symptoms usually represent a substantial burden, they significantly 
impair patients’ quality of life and level of functioning. Psychological factors like depression 
or anxiety as well as symptom-specific concerns or expectations are important contributors to 
high levels of health care use in these patients [6]. Repeated investigations and hospital 
treatment are frequent consequences and lead to high socio-economic costs. The health care 
burden due to persistent somatic symptoms is comparable to anxiety and depressive disorders, 
and there is a high co-morbidity between these disorders [7, 8].  Strategies to improve the 
early recognition and identification of patients with high somatic symptom burden is 
important to initiate adequate treatment [9].  
Standardized patient-reported outcome measures like self-report questionnaires are a 
good option to assess, quantify, and monitor common conditions in clinical, and especially in 
general practice. A frequent challenge in this context is to make precise assessments within a 
limited amount of time. Additionally, self-report represents a complementary source of 
information by capturing the patients’ own perspectives of their symptoms [10].  
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From a research perspective, it is important to assess the number, type and severity of 
somatic symptoms as change in symptoms will continue to be a central outcome feature of 
treatments for patients and physicians/therapists alike [11]. There are several standardized and 
validated instruments which effectively measure the patients’ burden due to specific somatic 
complaints (e.g. PHQ-15 [12], SSS-8 [13], SCL-90R or BSI [14]).  
The Patient Health Questionnaire PHQ-15 is one of the most frequently used 
instruments to identify people at risk for somatization. It has well-established psychometric 
properties, is available in multiple languages and has been recommended for use in large-
scale studies [15]. The PHQ-15 assesses the presence and severity of common somatic 
symptoms in primary care, such as fatigue, gastrointestinal, musculoskeletal, pain, and 
cardiopulmonary symptoms within the last four weeks using 15 items. Sum-scores range from 
0 to 30 and indicate the self-rated symptom burden with higher scores indicating higher 
burden (0-4 no-minimal; 5-9 low; 10-14 medium; 15-30 high). 
The Somatic Symptom Scale-8 (SSS-8) was developed within the process of the 
DSM-5 field trials as a measure of somatic symptom burden related to the new diagnosis of 
somatic symptom disorder (former title: Patient Health Questionnaire Somatic Symptom 
Short-Form, PHQ-SSS) [16]. It is an abbreviated 8-item version of the PHQ-15. The items of 
the SSS-8 were selected on the basis of symptom prevalence in primary care, association with 
measures of functioning, and statistical commonalities with the items of the complete scale. 
Some original items were condensed from two into one, and a few items were deleted.  A 5-
point response option (0-4) for each SSS-8 item and a 7-day time frame are used. Cut-off-
scores indicate whether a patient suffers from minimal (0-3 points), low (4-7), medium (8-11), 
high (12-15), or very high (16-32) somatic symptom burden. Gender and age specific norms 
are available [13]. Previous studies demonstrated good item characteristics and excellent 
reliability, a sound factor structure and significant associations with related constructs like 
depression, anxiety, quality of life, and health care use [13, 17]. The SSS-8 is available in 
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English, German, and Japanese [13, 17, 18], and its sensitivity to change has recently been 
demonstrated [19].  
Aims of the study 
Gierk and colleagues [17] examined within a sample of outpatients from a 
psychosomatic clinic in Germany whether both measures were comparable in terms of their 
psychometric properties and estimates of symptom burden. The correlation between both 
instruments was high (r = 0.83) and they showed similar results considering reliability and 
validity. The SSS-8 performed well as a short version of the PHQ-15. Also, analyses 
suggested that similar cut-points might be used for both measures in grading somatic 
symptom burden as mild, moderate or severe.  The aim of this paper is to replicate and extend 
the psychometric comparison of both measures using baseline data from a large clinical trial. 
Specifically, we compare the two measures in terms of item characteristics, reliability, and 
construct validity of the severity thresholds with regard to health related quality of life, 
functional impairment and work disability. 
Method  
Procedure and participants 
Data were drawn from the Comprehensive vs. Assisted Management of Mood and 
Physical Symptoms Study (CAMMPS: https://clinicaltrials.gov/ct2/show/NCT01757301), a 
randomized comparative effectiveness trial designed to test the relative effectiveness of a 
lower-resource vs. a higher-resource enhancement of usual primary care in the management 
of Veterans suffering from pain plus comorbid anxiety and/or depression. The trial enrolled a 
total of 294 patients between January 2014 and June 2016. Baseline data was used for all 
analyses in this study. All measures were interviewer-administered. The trial was approved by 
the Indiana University institutional review board and the Roudebush VAMC research review 
committee.  
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Somatic symptom measures 
The CAMMPS trial used a modified, 14 item version of the PHQ-15, hereinafter 
referred to as the PHQ-15m. The item on sexual pain and problems was left out for several 
reasons. First, it is the least commonly endorsed item in multiple epidemiological studies and 
also the one item that a subset of respondents are most uncomfortable answering. Second, the 
item has shown the lowest item-total correlation (0.33) of any of the PHQ-15 items, and all 
correlations with other items of the scale were low (<.20). Third, this item demonstrates 
among the lowest correlations with multiple domains of quality of life, disability and health 
care use. Fourth, in factor analysis, this item and the item on menstrual problems had the 
lowest commonality with the other 13 items and were excluded from the three factors 
(cardiopulmonary, gastrointestinal, and fatigue/pain) [12]. Fifth, reliability in terms of internal 
consistency (Cronbach α) for the modified 14 item version (PHQ-15m) ranged from 0.76 - 
0.77 in three large clinical trials [20-22],  which is similar to the reliability reported for the 
original PHQ-15 (Cronbach α = .80 [12]). Finally, these trials demonstrated the 
responsiveness to treatment of the PHQ-15m. The Somatic Symptom Scale-8 (SSS-8) was 
used in its original form [13]. 
Other Mental Health, Quality of Life and Disability Measures 
Depression was measured with the Patient Health Questionnaire 9-item depression 
scale (PHQ-9; [23] which assesses the presence of the nine DSM criteria for major depression 
within the last two weeks. Scores range from 0 to 27 and indicate the severity of depression 
(high scores reflect high symptom load).  
Anxiety was assessed with the7-item Generalized Anxiety Disorder Scale (GAD-7) 
[24], a self-administered patient questionnaire which is used as a screening tool and severity 
measure of both generalized anxiety disorder as well as other common anxiety disorders. 
Scores range from 0 (minimal) to 21 (severe). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
The Brief Pain Inventory (BPI) [25] is an 11-item self-administered questionnaire used 
to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily 
functioning. Patients are asked to rate their worst, least, average, and current pain intensity, , 
and the degree that pain interferes with general activity, mood, walking ability, normal work, 
relations with other persons, sleep, and enjoyment of life on a 0 (none) to 10 (worst) . We 
used the mean total pain score for our analyses. 
The 12-item Short Form Health Survey (SF-12) [26] is a measure of health-related 
quality of life from which a Physical Component Summary (PCS) score and Mental 
Component Summary (MCS) score can be derived. Both scores are standardized to a mean of 
50 and a standard deviation of 10 to facilitate the comparison of individuals within the general 
population. Higher scores correspond to better health related quality of life. 
The Sheehan Disability Index (SDI) [27] assesses functional impairment in three 
interrelated domains: work/school, social and family life. Each of its 3 items is scored from 0 
(unimpaired) to 10 (highly impaired), with the SDI score being a mean of the 3 items.  
In addition, patients reported the number of days in the past four weeks where they 
had to reduce their usual activities by 50% or more (range: 0 to 28), and provided information 
on sociodemographic characteristics.  
Statistical Analyses 
Because the PHQ-15 and SSS-8 were interviewer-administered, the amount of missing 
data at the item level was very low (1-2%) and comparable for both scales. To provide a 
conservative estimate of the scale score, a missing item was assigned a value of 0. We 
calculated means, standard deviations, corrected item-total-correlations and frequency 
distribution of responses per item for the PHQ-15m and the SSS-8. Reliability was assessed 
using Cronbach´s α. Pearson correlations between the PHQ-15m, SSS-8, PHQ-9, GAD-7, 
BPI, MCS, PCS, SDI and disability days were calculated. Percentile distributions of somatic 
symptom severity for the PHQ-15m and the SSS-8 were calculated. Incidence rate ratios 
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(IRR) for each 1-point change in PHQ-15m and SSS-8 in association with change in disability 
days were calculated using parameter estimates from negative binomial regression. In terms 
of clinically important differences, 1- and 2-standard error of measurement (SEM) changes in 
PHQ-15m and SSS-8 were calculated (where SEM = standard deviation times the square root 
of 1-Cronbach’s alpha) to quantify the increase in disability days that is associated with 
change in somatic symptom burden [28]. To study the comparability of the severity thresholds 
of both scales, we calculated the mean (SD) physical health-related quality of life (PCS), 
functional impairment (SDI) and disability days for groups of patients that were classified 
according to the different PHQ-15m and SSS-8 scoring cut-points. We quantified the 
between-scale differences using the standardized mean difference (Cohen´s d).  
Results   
Study sample 
Table 1 reports sociodemographic and psychopathological characteristics of the study 
sample. Participants had a mean age of 57.4 and were 87% male and 79% white, 
characteristic of a Veteran population.  Symptom and quality of life scores were in the 
moderate to moderately severe range as expected for patients with chronic pain and 
psychiatric comorbidity. 
Psychometric characteristics of PHQ-15m and SSS-8 
The mean (SD) sum-scores of the PHQ-15m and the SSS-8 were 16.7 (5.8) and 13.5 
(4.1), respectively. The correlation between the two scales was 0.79. The internal 
consistencies were α = 0.66 for the PHQ-15m and α = 0.72 for the SSS-8. As shown in Table 
2, the mean score for specific symptoms varied in both scales, which indicates that some 
somatic symptoms are reported more frequently and/or at a higher severity level than other 
symptoms. Pain, energy and sleep items had the highest mean scores, whereas dizziness had 
the lowest scores. Considering the differing response formats of both scales, frequency 
distributions of responses are comparable, with the items on chest pain and/or shortness of 
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breath being the least comparable. All corrected item-total correlations were > 0.50 for the 
SSS-8; several were lower (< 0.40) for the PHQ-15m.  
Association of somatic symptom burden with psychopathology, health-related quality of life, 
and disability. 
The PHQ-15m and the SSS-8 sum-scores were highly correlated (r = 0.79). As shown 
in Table 3, both scales showed a similar pattern of correlations with self-report measures of 
depression, anxiety, pain (BDI), physical and mental health-related quality of life, functional 
impairment, and disability days (CUTPH): Higher scores on the PHQ-15m and SSS-8 
correspond to higher levels of depression, anxiety, pain, functional impairment and disability 
days and lower levels of physical and mental health-related quality of life. 
Percentile distribution of PHQ-15m and SSS-8 scores 
Although the PHQ-15m and the SSS-8 have different numbers of items and a different 
response format, the sum-scores of both scales have a similar percentile distribution which is 
shown in Table 4. The comparability in the distribution is high (difference ≤ 3 points) up to 
the 50th percentile, however, it steadily decreases from the 60st percentile (difference = 4 
points) to the 99th percentile (difference = 8 points).  
Association of somatic symptom scores with disability days 
Patient-reported number of disability days in the past four weeks (i.e., number of days 
where individuals had to reduce their usual activities by 50% or more) had a range of 0 to 28 
days with a mean of 15.4 (9.4). Negative binomial regression analysis indicated that the PHQ-
15m and the SSS-8 both had significant and similar associations with disability days. A 1-
point increase in PHQ-15m (worsening of somatic symptoms) resulted in a 3.7% increment in 
the number of disability days (IRR = 1.037 [95% CI = 1.015; 1.061], z = 2.23, p <.0001). A 1-
point increase in SSS-8 (worsening in somatic symptoms) resulted in a 3.9% increment in the 
number of disability days (IRR = 1.039 [95% CI = 1.023; 1.055], z = 2.08, p <.0001). Using 
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the standard error of measurement (SEM) as an approach to estimate the minimal clinically 
important difference (MCID) for a scale, the SEM was 2.3 for the PHQ-15m 3.1 for the SSS-
8. A 1-SEM change in PHQ-15m and SSS-8 resulted in a 9.2% and 12.4% increase in 
disability days, respectively. A 2-SEM change in PHQ-15m and SSS-8 resulted in a 19.3% 
and 26.3% increase in disability days, respectively. 
Comparing two ways of classifying severity cut-points on the SSS-8 
To examine the comparability of the PHQ-15m and the SSS-8 severity categories, we 
compared – in accordance with Gierk et al. [17] – the physical health-related quality of life 
(SF-12 PCS) scores of patients who were grouped by the standard PHQ-15m severity 
thresholds and two ways of classifying SSS-8 severity thresholds. We additionally compared 
the groups with regard to their Sheehan Disability Index scores and number of disability days. 
To quantify the between-scale differences on these three outcomes, we calculated the 
standardized mean differences (Cohen´s d) for each severity category. The original PHQ-15m 
(0-4 no – minimal; 5-9 low; 10-14 medium; 15-30 high) and the original SSS-8 thresholds (0-
3 no – minimal; 4-7 low; 8-11 medium; 12-15 high; ≥ 16 very high) were applied. 
Additionally the standard PHQ-15m thresholds were applied to the SSS-8 (0-4 no-minimal; 5-
9 low; 10-14 medium; ≥ 15 high). Only two of the patients from our sample fell within any of 
the groups of no – minimum symptom burden, so that the results for this threshold group is 
not displayed. All other results are shown in Table 5. For all three outcomes, grouping 
patients according to the original SSS-8 severity thresholds led to higher group differences 
between the PHQ-15m and SSS-8 than using the PHQ-15m severity thresholds for the SSS-8. 
There are, however, two exceptions: in the low category for the SF-12 PCS and in the 
medium category for the SDI, the SSS-8 original scoring method led to smaller differences. 
Discussion 
The main aim of the study was to compare the psychometric properties of two 
instruments assessing somatic symptom burden: the PHQ-15 and the SSS-8. In an earlier 
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study, Gierk et al. [17] found comparable reliability and construct validity for both measures 
and therefore suggested the use of the SSS-8 as a more efficient alternative to the original 
PHQ-15, especially in clinical settings with limited assessment time or in research settings to 
reduce the measurement burden for study participants. Since the original study was based on a 
fairly small and selective sample of patients, the findings regarding alternative severity 
thresholds for the SSS-8 were considered preliminary. We used the PHQ-15m and SSS-8 
within a larger sample of 294 patients from a clinical trial involving patients with chronic pain 
and mood symptoms and compared the psychometric properties of both scales in order to 
support previous findings. In addition to the SF-12 MCS, we included two additional 
measures on impairment (SDI and disability days) to further validate severity thresholds.  
Cronbach´s α of the SSS-8 (0.72) and PHQ-15m (0.66) were similar, yet lower than in 
the original study (0.76 and 0.80, respectively). The higher Cronbach’s alpha for the SSS-8 
may be partly because the SSS-8 has more response options than the PHQ-15 (5 vs. 3). The 
correlation between the PHQ-15 and SSS-8 scores was higher than the Cronbach’s alpha of 
each scale, which is not surprising. Cronbach’s alpha is a measure of the internal reliability of 
the items constituting a scale. Somatic symptom scales include multiple individual symptoms 
which originate from different bodily organs or locations. Thus, one might expect greater 
heterogeneity among items in a somatic symptom scale than among items in other 
psychological scales (e.g., depression or anxiety). In contrast, each scale score is a single 
number representing the sum of the individual item scores. Also, the SSS-8 and PHQ-15 
include a number of items in common. 
The frequency distributions of responses, the mean item severity of specific 
symptoms, and the standard deviations within the scales were comparable considering the 
differing response formats of both scales. For both scales, the highest average scores were 
found for items on pain, energy and sleep which could be expected in a trial on mood and pain 
symptoms. The lowest average scores were found for dizziness. The items on chest pain 
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and/or shortness of breath showed the least comparable results which may be due to the fact 
that they have been combined into a single item in the SSS-8. Both items may be more 
relevant for patients with burdensome cardiopulmonary symptoms which were not the focus 
of our study. All item-total correlations were lower for the PHQ-15m which may in general be 
due to the heterogeneous latent structure of somatic symptom burden [29] which is even more 
salient to the PHQ-15m which consists of more items.  
The correlation between the SSS-8 and the PHQ-15m was high (0.79) and comparable 
to the findings by Gierk et al (0.83). Both measures showed substantial positive associations 
with depression and anxiety which is expected since there are high comorbidities between 
somatoform disorders and depression and anxiety disorders [8]. Associations with the Brief 
Pain Inventory (BPI) were similar and also substantial which is not surprising given the item 
overlap with regard to pain. Burdensome somatic symptoms are usually associated with 
decreased health-related quality of life, reduced daily activities and increased disability across 
different life domains [30, 31]. With regard to physical and mental health-related quality of 
life, both the PHQ-15m and SSS-8showed a substantial negative association (i.e. high 
symptom burden corresponded to poor health-related quality of life). Associations were 
substantially positive with respect to disability (i.e. high symptom burden corresponded to 
high impairment). When comparing the correlations of the PHQ-15 and SSS-8 with measures 
that were used in both Gierk’s study and our trial (GAD-7 anxiety, PHQ-9 depression, SF 
mental and physical health-related quality of life), correlations found in our study were 
slightly lower, with the SSS-8 showing higher associations than the PHQ-15m with all used.   
Looking at the percentile distributions, the comparability in the two scales was high up 
to the 50th percentile (difference ≤ 3 points) and steadily decreased from the 60st percentile 
on (differences between 4 and 8 points). These differences are greater than the ones found in 
Gierk et al [17].  Similar to Gierk et al., we found substantial differences in the severity 
estimation of the PHQ-15m and SSS-8 severity thresholds which could in general be reduced 
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by scoring the SSS-8 with the PHQ-15 thresholds. This supports a good correspondence 
between the SSS-8 and the PHQ-15m with data from a larger sample of patients from primary 
care, not only on the dimension of physical health-related quality of life, but also when 
measuring physical impairment (SDI) and disability days.  
Our study has a few limitations. First and for reasons discussed earlier, we used a 
modified version of the PHQ-15, the PHQ-15m, which limits the direct comparability of our 
study results to the ones found in Gierk et al. However, we would assume that the exclusion 
of the item on sexual pain and problems in the PHQ-15m makes both instruments more 
comparable since this particular item is not included in the SSS-8. Since it is also one of the 
items least endorsed, the average PHQ-15 sum-score should not be noticeably influenced by 
excluding this item.  Second, our study uses baseline data only, so that longitudinal questions 
like the effects of the different time frames of the PHQ-15m (i.e. symptom burden within the 
last 4 weeks) and the SSS-8 (i.e. symptom burden within the last 7 days) cannot be answered.  
Due to feasibility reasons, both questionnaires were presented to the patients at baseline as 
part of an interview-based set of measures. The PHQ-15m was administered first in all 
patients, so that possible carry-over effects cannot be excluded. 
Altogether the SSS-8 performed well as a brief measure of somatic symptom burden in 
primary care patients with mood and pain symptoms. Its psychometric properties were similar 
or even slightly better (i.e. higher correlations with other measures) than those of the PHQ-
15m. Taking into account all three different impairment measures, the estimates of symptom 
burden were very similar when the SSS-8 was scored with the PHQ-15 thresholds. Our results 
therefore support the idea of common scoring thresholds for both instruments. Since there is a 
growing impetus to incorporate patient-reported outcome measures into clinical practice [32] 
with the simultaneous need to consider competing demands for treating and managing many 
different acute and chronic conditions in clinical practice, our findings provide further support 
for the utility of the SSS-8 as a short measure for somatic symptom burden.  
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Table 1: Baseline data of the study sample (n = 294) 
Variable Total (n=294) 
 
N (%) or             
Mean (SD) 
Demographic  
Age 57.4 (12.1) 
Male sex 257 (87.4%) 
Race  
     White 233 (79.3%) 
     Black 45 (15.3%) 
     Other 16   (5.4%) 
  
Married 167 (56.8%) 
Education:  
     ≤ high school 76 (25.9%) 
     Some college or trade school 156 (53.1%) 
     College 62 (21.1%) 
Employment:  
     Employed 82 (27.9%) 
     Unemployed 112 (38.1%) 
     Retired 100 (34.0%) 
Scale Scores  
Somatic symptom burden (PHQ-15m) 13.5   (4.1) 
Somatic symptom burden (SSS-8) 16.7   (5.8) 
Depression severity (PHQ-9) 14.0   (5.2) 
Anxiety severity (GAD-7) 11.2   (5.1) 
Total Pain Score (BPI) 5.9   (1.7) 
Health-related quality of life / physical (SF-12 PCS) 33.2   (8.5) 
Health-related quality of life / mental (SF-12 MCS) 37.8 (10.7) 
Sheehan disability (SDI) 5.7   (2.3) 
Disability days past 4 weeks 15.4   (9.4) 
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Table 2: Frequency distribution of responses (%), means (SD), and item-total 
correlations for the items of the PHQ-15m and SSS-8 
Somatic Symptom 
(Scale) 
Not at all  
(both 
scales) 
A little bit 
(PHQ-15m) 
A little bit 
or  
Somewhat 
(SSS-8) 
A lot (PHQ-
15m) 
Quite a bit 
or 
Very much 
(SSS-8) 
Mean 
(SD)* 
Item 
Score 
Item-Total 
Correlation 
Headache (PHQ-15m) 34.7 36.7 28.6 0.9  
(0.8) 
0.49 
Headache (SSS-8) 40.8 34.3 24.8 1.4  
(1.4) 
0.62 
Dizziness (PHQ-15m) 41.5 43.5 15.0 0.7  
(0.7) 
0.54 
Dizziness (SSS-8) 51.7 37.1 11.2 0.9  
(1.1) 
0.52 
Back pain (PHQ-15m) 5.8 16.7 77.6 1.7  
(0.6) 
0.32 
Back pain (SSS-8) 8.5 17.6 73.8 2.9  
(1.3) 
0.65 
Feeling tired/having low 
energy (PHQ-15m) 
4.4 16.7 78.9 1.7  
(0.5) 
0.32 
Feeling tired/ having low 
energy (SSS-8) 
2.4 27.9 69.7 2.8  
(1.1) 
0.65 
Trouble sleeping (PHQ-
15m) 
7.1 13.3 79.6 1.7  
(0.6) 
0.37 
Trouble sleeping (SSS-8) 11.2 20.0 68.7 2.8  
(1.4) 
0.57 
Limb/joint pain (PHQ-
15m) 
1.7 11.2 87.1 1.9  
(0.4) 
0.17 
Limb/joint pain (SSS-8) 2.0 20.7 77.2 3.2  
(1.0) 
0.51 
Chest pain (PHQ-15m) 64.3 27.9 7.8 0.4  
(0.6) 
0.46 
Shortness of breath 
(PHQ-15m) 
41.8 36.7 21.4 0.8  
(0.8) 
0.53 
Chest pain or shortness of 
breath (SSS-8) 
41.2 43.5 15.3 1.1  
(1.2) 
0.53 
Stomach pain (PHQ-15m) 39.1 37.4 23.5 0.8  
(0.8) 
0.58 
Nausea/gas/indigestion 
(PHQ-15m) 
33.3 31.3 35.4 1.0  
(0.8) 
0.65 
Constipation/loose stools 
(PHQ-15m) 
37.1 29.6 33.3 1.0  
(0.8) 
0.59 
Stomach or bowel 
problems (SSS-8) 
30.6 35.5 34.0 1.7  
(1.5) 
0.60 
Fainting spells (PHQ-
15m) 
94.9 4.4 0.7 0.1  
(0.3) 
0.20 
Menstrual pain/problems 
(PHQ-15m) 
97.6 2.0 0.3 0.03 
(0.2) 
0.12 
Feeling heart pound/race 
(PHQ-15m) 
43.9 43.2 12.9 0.7  
(0.7) 
0.51` 
*The PHQ-15m asks how much a symptom bothered a patient in the past month; each item 
is scored from 0 (not at all) to 2 (bothered a lot). 
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 The SSS-8 asks how much a symptom bothered the patient in the past week; each item is 
scored from 0 (not at all) to 4 (very much). 
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Table 3: Pearson correlations of the PHQ-15m and SSS-8 sum-score with other scales 
Scale 
 
PHQ-15m 
 
P  
value 
SSS-8 
P  
value 
PHQ-9 depression   0.51 <.0001   0.53 <.0001 
GAD-7 anxiety score   0.35 <.0001   0.37 <.0001 
Brief Pain Inventory    0.28 <.0001   0.36 <.0001 
SF-12 PCS (physical) - 0.32 <.0001 - 0.40 <.0001 
SF-12 MCS (mental) - 0.32 <.0001 - 0.37 <.0001 
Sheehan Disability Index   0.41 <.0001   0.46 <.0001 
Disability days in past 4 weeks   0.25 <.0001   0.35 <.0001 
 
Note: PHQ-15m = Patient Health Questionnaire – 15, modified version. SSS-8 = Somatic Symptom 
Scale-8.  PHQ-9 = Patient Health Questionnaire Depression Scale-9.  GAD-7 = Generalized Anxiety 
Disorder Scale-7. SF-12 PCS = Physical Component Summary score of the SF-12 health-related 
quality of life scale. SF-12 = Mental Component Summary score of the SF-12. 
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Table 4: Percentile distribution of PHQ-15m and SSS-8 sum-scores (n = 294) 
Percentile 
 
PHQ-15m  
Score 
 
SSS-8  
Score 
1 5 5 
5 7 7 
10 8 9 
20 10 11 
30 11 13 
40 12 15 
50 14 17 
60 15 19 
70 16 20 
80 17 22 
90 19 24 
95 20 26 
99 23 31 
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Table 5 Construct validity of PHQ-15m and SSS-8 severity categories (n = 294) 
 
Severity 
SF-12 Physical Component (PCS), mean (SD) Standardized differences* 
1. PHQ-15 
original a 
2. SSS-8 
original b 
3. SSS-8 with 
PHQ-15 
scoring c 
1. vs. 2. 1. vs. 3. 
Low 38.2 (10.0) 37.9 (9.4) 37.1 (8.9) 0.03 0.12 
Medium 34.2 (8.0) 38.5 (9.0) 37.2 (8.1) 0.51 0.37 
High 30.2 (7.1) 34.7 (7.6) 30.6 (7.3) 0.61 0.06 
Very high d  30.7 (7.6)    
 
Severity 
Sheehan Disability Index, mean (SD) Standardized differences* 
1. PHQ-15 
original a 
2. SSS-8 
original b 
3. SSS-8 with 
PHQ-15 
scoring c 
1. vs. 2. 1. vs. 3. 
Low 4.4 (2.6) 3.5 (2.6) 4.5 (2.1) 0.35 0.04 
Medium 5.1 (2.2) 4.8 (1.9) 4.6 (2.3) 0.15 0.22 
High 6.8 (1.9) 4.9 (2.4) 6.4 (2.1) 0.88 0.20 
Very high d  6.5 (2.0)    
 
Severity 
Disability Days in Past 4 Weeks, mean (SD) Standardized differences* 
1. PHQ-15 
original a 
2. SSS-8 
original b 
3. SSS-8 with 
PHQ-15 
scoring c 
1. vs. 2. 1. vs. 3. 
Low 12.7 (9.5) 9.3 (8.3) 9.8 (8.3) 0.38 0.33 
Medium 14.3 (9.2) 11.9 (10.0) 13.3 (9.6) 0.25 0.11 
High 17.8 (9.1) 13.6 (8.8) 17.4 (8.9) 0.47 0.04 
Very high d  17.8 (8.9)    
* Standardized differences are computed as the mean difference divided by the pooled standard 
deviations (Cohen´s d). 
a 0-4 no-minimal (n = 2)e, 5-9 low (n = 47), 10-14 medium (n = 121), and 15-30 high (n = 124) 
b 0-3 no-minimal (n = 0)e, 4-7 low (n = 16) , 8-11 medium (n = 44), 12-15 high (n = 70), and 16-32 very 
high (n = 164) 
c 0-4 no-minimal (n = 1)e, 5-9 low (n = 31), 10-14 medium (n = 81), and 15-32 very high (n = 181) 
d only available for the SSS-8 original scoring method 
e not reported in the table, because of n ≤ 2 
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Highlights 
 The PHQ-15m and the SSS-8 are comparable measures  
 The SSS-8 is a short alternative to PHQ-15 in settings with limited assessment time 
 Patient-reported outcome measures should be incorporated into clinical practice  
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